The actions of amylobarbitone sodium, butobarbitone and quinalbarbitone sodium upon insomnia and nocturnal restlessness compared in psychiatric patients.
Amylobarbitone sodium, butobarbitone, quinalbarbitone sodium, and a placebo were compared in a controlled, double-blind trial in psychiatric patients with insomnia. An apparatus recording movement in bed is described, with sleep assessments by night nurses and patients. All three barbiturates significantly reduced movement and gave significantly longer, less broken and sounder sleep, without increased incidence of "hang-over." There was no follow-on effect from night to night. With effective doses there was no significant difference between these barbiturates in onset and duration of hypnotic action, although usually accepted as either short or intermediate acting.
D000328:Adult; D000654:Amobarbital; D001463:Barbiturates / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives; D008297:Male; D011595:Psychomotor Agitation; D012631:Secobarbital; D012890:Sleep; D007319:Sleep Initiation and Maintenance Disorders / Q000628:therapy*; D012964:Sodium
D001463:Barbiturates; D006993:Hypnotics and Sedatives; D012631:Secobarbital; D012964:Sodium; D000654:Amobarbital; C027712:butobarbital
BARBITURATES/therapy; INSOMNIA/therapy